Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 8/20 | 0.86 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.86 |
| ▸ | KDR | P35968 | 5/20 | 0.86 |
| ▸ | ETV6 | P41212 | 5/20 | 0.86 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.86 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.86 |
| ▸ | AURKA | O14965 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821102 | 1.00 | FGFR4 (0.86) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL298446 | 0.92 | FGFR4 (1.00) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL298445 | 0.92 | FGFR4 (1.00) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL29627000 | 0.92 | FGFR4 (1.00) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL297689 | 0.92 | FGFR4 (1.00) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL297690 | 0.92 | FGFR4 (1.00) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL891766 | 0.92 | FGFR4 (0.98) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL891769 | 0.92 | FGFR4 (0.98) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL891767 | 0.92 | FGFR4 (0.98) | FGFR4FGFR1KDRETV6FGFR2 | |
| Ly-2874455 SCHEMBL891768 | 0.92 | FGFR4 (0.98) | FGFR4FGFR1KDRETV6FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20160375142-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20160108380-A1 | FUSION PROTEINS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
| US-20150203589-A1 | FUSION PROTEINS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108380-A1 | FUSION PROTEINS AND METHODS THEREOF | BCR, RPS27A, FUS | FGFR4 193/4885FGFR1 223/4885KDR 2053/4885 |
| US-20160375142-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | FGFR4 1999/4885FGFR1 1030/4885KDR 1715/4885 |
| US-20150203589-A1 | FUSION PROTEINS AND METHODS THEREOF | BCR, RPS27A, FUS | FGFR4 193/4885FGFR1 223/4885KDR 2053/4885 |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | FGFR4 1493/4885FGFR1 1732/4885KDR 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.